Tolfenamic acid treatment at 50 μM for 48 h produced predominantly downregulated genes in L3.6pl pancreatic cancer cells, with 704 down versus 253 up. Under the same treatment conditions, MIA PaCa-2 cells showed predominantly upregulated genes, with 211 up versus 107 down. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Genes differentially expressed by TA treatment in L3.6pl cells
Cell-based study · L3.6pl pancreatic cancer cells [1]
L3.6pl pancreatic cancer cells were treated with Tolfenamic acid at 50 μM for 48 h, with equivalent DMSO treatment as the control. Differential gene expression analysis showed predominantly downregulated genes: 704 down versus 253 up.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM
- Exposure duration
- 48 h
- Method
- added directly to the media
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Tolfenamic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Cell lines (S33); MATERIALS AND METHODS > Treatment (S36, S38, S39); MATERIALS AND METHODS > Microarray analysis (S40)
Differential gene expression: Differential gene expression; comparator: Control cells were treated with equivalent amounts of DMSO. — RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Microarray analysis (S40)
Genes affected by TA in MIA PaCa-2
Cell-based study · MIA PaCa-2 [1]
MIA PaCa-2 cells were treated with Tolfenamic acid at 50 μM for 48 h, with equivalent DMSO treatment as the control. Differential gene expression analysis showed predominantly upregulated genes: 211 up versus 107 down.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM
- Exposure duration
- 48 h
- Method
- added directly to the media
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Tolfenamic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Cell lines (S31); MATERIALS AND METHODS > Treatment (S36, S38, S39); MATERIALS AND METHODS > Microarray analysis (S40)
Differential gene expression: Differential gene expression; comparator: Control cells were treated with equivalent amounts of DMSO. — RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Microarray analysis (S40)